09:42 AM EDT, 07/17/2025 (MT Newswires) -- Okyo Pharma ( OKYO ) said Thursday it received $1.9 million in non-dilutive funding that will be used to accelerate the development of urcosimod, its lead candidate for neuropathic corneal pain.

Okyo Pharma ( OKYO ) said the capital will help expand its research and development efforts without diluting shareholder equity.

Price: 2.87, Change: -0.09, Percent Change: -3.14